Oral anticoagulants found to be more effective and cost-effective than heparin for cancer-associated thrombosis

A cost-effectiveness analysis comparing direct oral anticoagulants (DOACs) to low-molecular-weight heparin (LMWH) found that DOACs are both more medically effective and cost-effective than LMWH when treating cancer-associated thrombosis (CAT). These findings may inform decisions on the clinical level as well as policy decisions. The analysis is published in Annals of Internal Medicine.

source https://medicalxpress.com/news/2022-12-oral-anticoagulants-effective-cost-effective-heparin.html